Molecular Imaging and Biology最新文献

{"title":"The Imaging Value of ¹⁸F-FAPI PET/CT in Sorafenib-Induced Cardiac Dysfunction in Patients with Hepatocellular Carcinoma: Compared with ¹⁸F-FDG PET/CT.","authors":"Yingqi Luo, Qingqi Yang, Xiaowen Qin, Boyang Yu, Shengnan Jiang, Ying Liu","doi":"10.1007/s11307-025-02005-4","DOIUrl":"10.1007/s11307-025-02005-4","url":null,"abstract":"<p><strong>Purpose: </strong>Evaluation of ¹⁸F-FAPI PET/CT imaging in sorafenib-induced cardiac dysfunction in hepatocellular carcinoma (HCC) patients, and compared with ¹⁸F-FDG PET/CT.</p><p><strong>Procedures: </strong>This retrospective study enrolled 75 HCC patients treated with sorafenib at our institution from June 2021 to June 2023. All patients underwent ¹⁸F-FDG PET/CT six months after treatment, followed by ¹⁸F-FAPI PET/CT within the subsequent week. Patients were divided into cardiac dysfunction group and control group based on the definition of cancer therapy-related cardiac dysfunction (CTRCD). Myocardial uptake parameters on ¹⁸F-FDG and ¹⁸F-FAPI PET/CT were compared between the two groups. The primary endpoint was the occurrence of major adverse cardiac events (MACEs), and the secondary endpoint was all-cause mortality, with follow-up at 30, 90, and 180 days after the PET/CT examinations.</p><p><strong>Results: </strong>This study ultimately enrolled 47 patients, with the cardiac dysfunction group (n = 9) and control group (n = 38) demonstrating significant differences in myocardial ¹⁸F-FAPI high uptake, left ventricular (LV) ¹⁸F-FDG SUV, LV/liver ¹⁸F-FDG SUV, myocardial ¹⁸F-FAPI SUV, myocardial/aorta ¹⁸F-FAPI SUV, and myocardial/liver ¹⁸F-FAPI SUV. One year after treatment, the incidence of MACEs was slightly higher in the group with high ¹⁸F-FAPI myocardial uptake compared to the low uptake group (19.5% vs. 14.0%, log-rank p = 0.621), and the overall survival rate was lower in the high uptake group compared to the low uptake group (57.9% vs. 65.8%, log-rank p = 0.503).</p><p><strong>Conclusions: </strong>The myocardial uptake parameters of ¹⁸F-FDG and ¹⁸F-FAPI PET/CT are helpful in evaluating sorafenib-induced cardiac dysfunction in HCC patients. The level of ¹⁸F-FAPI myocardial uptake has potential value in predicting post-treatment cardiotoxicity and overall survival prognosis in HCC patients.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"324-332"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiogenomic Profiling for Survival Analysis in Gastric Cancer: Integrating CT Imaging, Gene Expression, and Clinical Data.","authors":"Anju R Nath, Kiruthika Thenmozhi, Jeyakumar Natarajan","doi":"10.1007/s11307-025-02019-y","DOIUrl":"10.1007/s11307-025-02019-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to integrate CT (Computed Tomography) radiomic features, gene expression profiles, and clinical data to identify radiogenomic biomarkers and improve overall survival prediction in gastric cancer (GC) patients.</p><p><strong>Procedures: </strong>Quantitative radiomic analysis was performed on 37 GC CT images, alongside gene expression and clinical data, to identify biomarkers associated with overall survival. Tumor segmentation and radiomic feature extraction were followed by Pearson correlation for feature selection. Gene Set Enrichment Analysis (GSEA) identified pathways linking gene expression changes with radiomic features. Regression models were applied to explore the relationships between these pathways, radiomic features, and clinical data in survival prediction.</p><p><strong>Results: </strong>A total of 107 radiomic features were extracted, with 46 radiomic features, 1,032 genes, and one clinical feature (age) selected for further analysis. GSEA identified 29 significant KEGG pathways, mainly involving immune, signal transduction, and catabolism pathways. In survival analysis, the SVM model performed best, identifying age, genes CSF1R and CXCL12, and image features ShortRunHighGrayLevelEmphasis and Idn (Inverse Difference Normalized) as independent predictors.</p><p><strong>Conclusion: </strong>This study highlights the potential of integrating imaging, genomics, and clinical data for prognosis in GC patients, with identified genes suggesting new radiogenomic biomarker candidates for future evaluation.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"353-364"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Analysis of ¹⁸F-FDG PET Radiomics and mRNA Expression in Recurrent/Metastatic Oral Squamous Cell Carcinoma: A Cross-Sectional Study.","authors":"Mai Kim, Wenchao Gu, Reika Kawabata- Iwakawa, Shinichiro Kina, Takahito Nakajima, Tetsuya Higuchi, Masaru Ogawa, Keisuke Suzuki, Yoshito Tsushima, Satoshi Yokoo","doi":"10.1007/s11307-025-02012-5","DOIUrl":"10.1007/s11307-025-02012-5","url":null,"abstract":"<p><strong>Background: </strong>This study explored the relationship between mRNA expression profiles obtained through next-generation sequencing (NGS) and ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG PET) texture analysis in patients with treatment-resistant oral squamous cell carcinoma (OSCC) who were treated with molecular-targeted drugs. We analyzed the correlation between ¹⁸F-FDG PET texture features and NGS data in a small cohort of five patients with recurrent or metastatic OSCC who received molecular-targeted drugs after surgery. Patients were categorized into two groups based on treatment response: responders (n = 3) and non-responders (n = 2). To validate our findings, we examined transcriptomic data from 292 OSCC patients in The Cancer Genome Atlas (TCGA) database.</p><p><strong>Results: </strong>The gene ankyrin repeat and SOCS box containing two (ASB2) was significantly overexpressed in non-responders and strongly correlated with specific PET radiomic features, including GLRLM_GLNU, GLRLM_RLNU, and GLZLM_GLNU (p < 0.05). High ASB2 expression was also associated with poor prognosis in OSCC patients (p < 0.05) and decreased overall survival, as shown by Kaplan-Meier analysis of the TCGA database (p = 0.017).</p><p><strong>Conclusions: </strong>Integrating ASB2 expression data with ¹⁸F-FDG PET texture features could potentially improve the prediction of treatment outcomes in treatment-resistant OSCC patients undergoing molecular-targeted therapy.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"421-430"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of ¹⁸F-Labeled Deuterated Tropane Derivatives with High Metabolic Stability for PET Imaging of the Dopamine Transporter.","authors":"Jingjing Hong, Jing Kang, Jiaojiao Zuo, Yi Fang, Chunyi Liu, Jingwen Li, Zhengping Chen","doi":"10.1007/s11307-025-02018-z","DOIUrl":"10.1007/s11307-025-02018-z","url":null,"abstract":"<p><strong>Purpose: </strong>Dopamine transporter (DAT) in the central nervous system is an attractive biomarker for the diagnosis and study of various neurodegenerative diseases. To develop in vivo metabolically stable positron emission tomography (PET) probes for DAT imaging with a high target/background ratio, two ¹⁸F-labeled tropane derivatives with deuteration on both the N-fluoropropyl and 2β-carbomethoxy groups of the tropane scaffold were synthesized and evaluated.</p><p><strong>Methods: </strong>Radioligands [¹⁸F]6 and [¹⁸F]10 were synthesized from anhydroecgonine and radiolabeled with ¹⁸F through a \"two-step one-pot\" method. Lipophilicity, in vitro binding assay and microPET imaging in rats were performed. [¹⁸F]10 showed a higher standardized uptake value ratio (SUVr) and was selected for further evaluations by in vivo metabolism and biodistribution.</p><p><strong>Results: </strong>The radioligands [¹⁸F]6 and [¹⁸F]10 were obtained in radiochemical purities > 98% and molar activity of about 30 GBq/μmol. [¹⁸F]6 or [¹⁸F]10 demonstrated high specificity and binding affinity to DAT in vitro, with IC₅₀ values between 2 ~ 3 nM. MicroPET imaging in wild type Sprague-Dawley rats revealed that [¹⁸F]10 has a higher SUVr than [¹⁸F]6. Blocking experiments demonstrated the selectivity and reversibility of [¹⁸F]10 for DAT binding in microPET imaging. The diagnostic efficacy of [¹⁸F]10 for DAT-related disorders was verified in semi-PD model rats with microPET. In vivo metabolic studies in rats indicated that [¹⁸F]10 exhibited enhanced stability. Biodistribution experiments further confirmed that [¹⁸F]10 accumulated in the DAT-rich region of the striatum.</p><p><strong>Conclusion: </strong>[¹⁸F]10 is a highly promising metabolically stable ¹⁸F-labeled PET probe for DAT imaging, with potential clinical applications in detecting and monitoring DAT-related neurological disorders.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"431-441"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry in ¹⁷⁷Lu-PSMA-617 Radioligand Therapy.","authors":"Christian Happel, Larissa Völler, Benjamin Bockisch, Daniel Groener, Britta Leonhäuser, Frank Grünwald, Amir Sabet","doi":"10.1007/s11307-025-01998-2","DOIUrl":"10.1007/s11307-025-01998-2","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC) with ¹⁷⁷Lu-PSMA (RLT) requires sufficient dose monitoring of the kidneys. Currently, dosimetry using SPECT/CT-imaging is the most preferred method. However, SPECT/CT is a time-consuming procedure and comprises additional radiation exposure to the patient. Moreover, not every therapeutic nuclear medicine facility has access to SPECT/CT. Therefore, the aim of this study was to develop a new procedure of kidney dosimetry without the use of SPECT/CT and evaluate this method in a large cohort of patients with mCRPC undergoing RLT.</p><p><strong>Procedures: </strong>A dedicated torso phantom with kidneys filled with a solution of ¹⁷⁷Lu-PSMA was used for quantitative calibration of a SPECT-camera. The calculated sensitivity was adapted according to the individual attenuation of the patient in four directions from the kidney surface to the body surface (ventral, dorsal, left and right) obtained from a previously performed CT. A total of 196 patients undergoing 926 cycles of ¹⁷⁷Lu-PSMA therapy were retrospectively analyzed. Abdominal SPECT was performed 24, 48 and 72 h after administration of ¹⁷⁷Lu-PSMA including scatter and dead-time correction in every patient. Kidney dose was calculated using an individual attenuation-based procedure and compared to values from international literature.</p><p><strong>Results: </strong>Volumes of interest of the kidneys were drawn in the three sequential SPECT-images to calculate intra-renal effective half-life. Absolute quantification of activity in the kidneys was accomplished obtaining a patient individual sensitivity based on the individual attenuation in the patient. Kidney dose was then calculated applying a bi-exponential time activity curve in Microsoft EXCEL. Mean kidney dose per administered activity was 0.54 (± 0.26) Gy/GBq.</p><p><strong>Conclusions: </strong>With the presented procedure a reliable kidney dosimetry is possible without the use of SPECT/CT. Facilities without SPECT/CT are therefore able to perform an adequate kidney dosimetry without additional radiation exposure for the patient.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"400-409"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[⁶⁸Ga]Ga-PSMA-11 PET/CT and [¹⁸F]Fluorocholine PET/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial.","authors":"Mohsen Beheshti, Malihe Shahbazi-Akbari, Marcus Hacker, Wolfgang Loidl, Werner Langsteger","doi":"10.1007/s11307-025-02020-5","DOIUrl":"https://doi.org/10.1007/s11307-025-02020-5","url":null,"abstract":"<p><strong>Purpose: </strong>There are few prospective studies addressed toward the role of ⁶⁸Gallium-labelled prostate-specific membrane antigen-11 ([⁶⁸Ga]Ga-PSMA-11) compared to [¹⁸F]Fluorocholine ([¹⁸F]FCH) PET/CT in clinical decision-making as prostate-specific PET-tracers. This study aims to evaluate the impact of PET/CT using [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FCH in clinical management of recurrent prostate cancer (PCa) and correlates imaging findings with clinical characteristics of PCa.</p><p><strong>Procedures: </strong>Forty-six patients with PCa (mean age 68.3 ± 6.3 years) with biochemical recurrence were enrolled in this prospective crossover trial. All patients underwent both [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FCH PET/CT within a maximum interval of 12 days (median 7d). A standard randomization tool randomized the sequence of PET/CT imaging. Clinical decision-making occurred in an interdisciplinary meeting considering PET/CT findings. PET/CT-blinded readings were performed 3 months after imaging followed by a consensus meeting for final interpretation of detected lesions.</p><p><strong>Results: </strong>Both imaging modalities detected 136 total malignant lesions. [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FCH PET/CT detected 125 and 60 lesions with a sensitivity of 96% and 48%, respectively. Tumor-to-background ratios and semi-quantitative PET parameters on [⁶⁸Ga]Ga-PSMA-11 were significantly higher in 54 (41.2%) tracer-avid congruent lesions detected on both imaging modalities. [⁶⁸Ga]Ga-PSMA-11 PET/CT exclusively detected 71 (52.2%) lesions, while 6 (4.4%) lesions were solely seen on [¹⁸F]FCH PET/CT. [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]FCH PET/CT were positive in 35/46 (76%) and 26/46 (57%) patients, respectively. PET/CT imaging led to a major treatment change in 4 (8.7%) patients, of which [¹⁸F]FCH PET/CT had superior impact in one patient.</p><p><strong>Conclusions: </strong>[⁶⁸Ga]Ga-PSMA-11 PET/CT revealed superior diagnostic performance to [¹⁸F]FCH PET/CT in patients with recurrent PCa, specifically with very low PSA levels ≤ 1 ng/ml. Moreover, it led to more accurate staging and clinical management of the disease. [¹⁸F]FCH PET/CT may play a complementary role in rare, select high-risk cases with negative [⁶⁸Ga]Ga-PSMA-11 PET/CT and ongoing ADT.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody.","authors":"Kevin Wyszatko, Nancy Janzen, Napoleon Law, Manuela Ventura, Teesha Komal, Neil Savage, Chitra Venugopal, Jacek M Kwiecien, Sheila K Singh, Saman Sadeghi","doi":"10.1007/s11307-025-02013-4","DOIUrl":"https://doi.org/10.1007/s11307-025-02013-4","url":null,"abstract":"<p><strong>Purpose: </strong>Targeted radionuclide therapy against cancer stem cell-specific markers, such as CD133, constitutes a promising strategy to eliminate resilient cancer stem cells for improved outcomes in refractory tumors. Here, we report the synthesis and evaluation of [¹⁷⁷Lu]Lu-DOTA-RW03, a CD133-targeted radioimmunotherapy.</p><p><strong>Procedures: </strong>A fully human, anti-CD133 antibody (RW03) was conjugated with DOTA-NHS and radiolabeled with lutetium-177 to yield [¹⁷⁷Lu]Lu-DOTA-RW03. Radioligand binding assays on [¹⁷⁷Lu]Lu-DOTA-RW03 were performed using CD133 expressing HT-29 cells to determine binding affinity and immunoreactive fraction. Immunodeficient mice (n = 15) bearing HT-29 tumors were divided into 4 cohorts to establish the biodistribution of [¹⁷⁷Lu]Lu-DOTA-RW03 at 24, 48, and 96 h post-injection (n = 5 per cohort). Additional biodistribution and SPECT imaging studies were performed to establish tumor specificity and dose-dependent tumor uptake. In a dose-escalation therapy study, HT-29 tumor bearing mice (n = 20) were treated with either 4.0 ± 0.1, 9.6 ± 0.1, or 14.1 ± 0.2 MBq of [¹⁷⁷Lu]Lu-DOTA-RW03 or a vehicle control (n = 5 mice per cohort). Tumors from the therapy study were processed ex vivo for immunohistochemical and histopathological analysis.</p><p><strong>Results: </strong>Radioimmunoconjugate [¹⁷⁷Lu]Lu-DOTA-RW03 (4.4 ± 0.1 DOTA per antibody) was isolated in 50 ± 10% radiochemical yield, 17-28 GBq/µmol molar activity, and in > 98% radiochemical purity. In vitro, the radiolabeled antibody exhibited excellent binding affinity (0.30 ± 0.03 nM) and > 75% immunoreactivity. The biodistribution of [¹⁷⁷Lu]Lu-DOTA-RW03 revealed notable tumor uptake (65 ± 5%ID/g, 96 h post-injection) and a favorable tumor-to-blood ratio (5:1, 96 h post-injection). In vivo antigen specificity was confirmed by a significant reduction (75%) in tumor uptake when [¹⁷⁷Lu]Lu-DOTA-RW03 was co-administered with a 200-fold molar excess of unlabeled RW03. The radioimmunoconjugate exhibited promising therapeutic efficacy in the treatment of CD133 expressing colorectal xenograft mouse model, with dose-dependent reductions in tumor growth rate and increased survival time. Histopathological and immunohistochemical analyses revealed elevated cell proliferation and extensive liquefactive necrosis at late stages into treatment, which provides an opportunity for multidosing and combination treatment strategies.</p><p><strong>Conclusions: </strong>These findings underscore the potential of [¹⁷⁷Lu]Lu-DOTA-RW03 as an effective therapy through targeting CD133 expressing cancer cells.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual and Quantitative ¹⁸F-FDG PET Tumor-liver Ratio in Radioiodine Refractory Differentiated Thyroid Cancer: Prognostic and Potential Predictive Value.","authors":"Xian Li, Hanhui Liu, Shenghong Zhang, Han Zhang, Jiajia Zhang, Shanshan Qin, Fei Yu","doi":"10.1007/s11307-025-02017-0","DOIUrl":"https://doi.org/10.1007/s11307-025-02017-0","url":null,"abstract":"<p><strong>Purpose: </strong>The progression rate and course of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) vary significantly, yet there lacks a precise method for predicting its progression. We hypothesized that using the liver as a reference organ can enable selective patient stratification. We aimed to establish fluorine-18 fluorodeoxyglucose positron emission tomography ([¹⁸F] FDG-PET) tumor to-liver ratio (TLR score) to predict outcome for RAIR-DTC.</p><p><strong>Procedures: </strong>This study included 64 patients with RAIR-DTC undergoing baseline ¹⁸F-FDG PET/CT. Patients were categorized by visual TLR (vTLR) into high (most lesions show higher uptake than the liver) or low (most lesions show lower uptake than the liver) groups using 3D maximum intensity projection (MIP) images. Quantitative TLR (qTLR) scores, including qTLR max (tumor SUVmax/liver SUVmax) and qTLRmean (tumor SUVmean/liver SUVmean), were semiautomatically derived from baseline PET, with high (≥ 1.5) and low (< 1.5) groups defined. Outcome data were progression-free survival (PFS).</p><p><strong>Results: </strong>Among 64 patients, the distribution of high-TLR versus low-TLR groups varied across scoring methods: vTLR score allocated 36 (56.3%) high vs 28 (43.7%) low, qTLRmax score identified 29 (45.3%) high vs 35 (54.7%) low, and qTLRmean score demonstrated the most divergent pattern with 21 (32.8%) high vs 43 (67.2%) low. Agreement among qTLRmax, vTLR and qTLRmean score was moderate (Fleiss weighted k, 0.579). The median PFS of the high and low groups by vTLR score was 16.0, 29.0 months (P = 0.010) respectively, by qTLRmax score was 14.0, 27.0 months (P = 0.041), respectively, by qTLRmean score was 14.0, 28.0 months (P = 0.004), respectively.</p><p><strong>Conclusions: </strong>The TLR score was prognostic for PFS of RAIR-DTC. The vTLR score assessed on 3D MIP PET images yielded substantial reproducibility and combining qTLR score provided reliable prognostic value.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET Imaging of a Transgenic Tau Rat Model SHR24 with [¹⁸F]AV1451.","authors":"Nisha K Ramakrishnan, Annie Ziyi Zhao, Stephen Thompson, Selena Milicevic Sephton, David J Williamson, Tomáš Smolek, Norbert Žilka, Franklin I Aigbirhio","doi":"10.1007/s11307-024-01972-4","DOIUrl":"10.1007/s11307-024-01972-4","url":null,"abstract":"<p><strong>Purpose: </strong>Positron Emission Tomography (PET) scans with radioligands targeting tau neurofibrillary tangles (NFT) have accelerated our understanding of the role of misfolded tau in neurodegeneration. While intended for human research, applying these radioligands to small animals establishes a vital translational link. Transgenic animal models of dementia, such as the tau rat SHR24, play a crucial role in enhancing our understanding of these disorders. This study aims to evaluate the utility of SHR24 rat model for PET studies.</p><p><strong>Procedures: </strong>Dynamic PET scans were conducted in male SHR24 rats and their wild-type SHR (SHRwt) littermates using [¹⁸F]AV1451. Rapid blood sampling and metabolite analysis were performed to acquire input curves. Time activity curves were obtained from various brain regions over 60 min. Blood-based, 2-Tissue Compartment Model (2-TCM) and Logan graphical analysis were used to obtain kinetic modelling parameters. The ability of reference tissue models to predict the binding potential (BP_ND) were assessed. Autoradiography studies were performed to corroborate the scan data.</p><p><strong>Results: </strong>Total distribution volume (V_T) was the best predicted parameter which revealed significantly higher uptake of [¹⁸F]AV1451 in the cortex (5.8 ± 1.1 vs 4.6 ± 0.7, P < 0.05) of SHR24 rats compared to SHRwt rats. Binding potential obtained from 2-TCM was variable, however BP_ND from reference tissue models detected significantly higher binding in cortex (0.28 ± 0.07 vs 0.20 ± 0.04, P < 0.01 by SRTM) and brainstem (0.14 ± 0.04 vs 0.08 ± 0.02, P < 0.01, by SRTM).</p><p><strong>Conclusions: </strong>With the ability to detect binding of established radioligand [¹⁸F]AV1451 in these rats, we have demonstrated the utility of this model for assessing aggregated tau neurobiology by PET, with reference tissue models providing potential for longitudinal studies.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"238-249"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential of Radiomics, Dosiomics, and Dose Volume Histograms for Tumor Response Prediction in Hepatocellular Carcinoma following ⁹⁰Y-SIRT.","authors":"Zahra Mansouri, Yazdan Salimi, Ghasem Hajianfar, Luisa Knappe, Nicola Bianchetto Wolf, Genti Xhepa, Adrien Gleyzolle, Alexis Ricoeur, Valentina Garibotto, Ismini Mainta, Habib Zaidi","doi":"10.1007/s11307-025-01992-8","DOIUrl":"10.1007/s11307-025-01992-8","url":null,"abstract":"<p><strong>Purpose: </strong>We evaluate the role of radiomics, dosiomics, and dose-volume constraints (DVCs) in predicting the response of hepatocellular carcinoma to selective internal radiation therapy with ⁹⁰Y with glass microspheres.</p><p><strong>Methods: </strong>^99mTc-macroagregated albumin (^99mTc-MAA) and ⁹⁰Y SPECT/CT images of 17 patients were included. Tumor responses at three months were evaluated using modified response evaluation criteria in solid tumors criteria and patients were categorized as responders or non-responders. Dosimetry was conducted using the local deposition method (Dose) and biologically effective dosimetry. A total of 264 DVCs, 321 radiomic features, and 321 dosiomic features were extracted from the tumor, normal perfused liver (NPL), and whole normal liver (WNL). Five different feature selection methods in combination with eight machine learning algorithms were employed. Model performance was evaluated using area under the AUC, accuracy, sensitivity, and specificity.</p><p><strong>Results: </strong>No statistically significant differences were observed between neither the dose metrics nor radiomicas or dosiomics features of responders and non-responder groups. ⁹⁰Y-dosiomics models with any given set of inputs outperformed other models. This was also true for ⁹⁰Y-radiomics from SPECT and SPECT-clinical features, achieving an AUC, accuracy, sensitivity, and specificity of 1. Among MAA-dosiomic and radiomic models, two models showed AUC ≥ 0.91. While the performance of MAA-dose volume histogram (DVH)-based models were less promising, the ⁹⁰Y-DVH-based models showed strong performance (AUC ≥ 0.91) when considered independently of clinical features.</p><p><strong>Conclusion: </strong>This study demonstrated the potential of ^99mTc-MAA and ⁹⁰Y SPECT-derived radiomics, dosiomics, and dosimetry metrics in establishing predictive models for tumor response.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":"201-214"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}